Skip to main content
. 2018 Apr 6;11:1997–2005. doi: 10.2147/OTT.S158114

Figure 2.

Figure 2

Representative images of radiography and pathology after presurgical TMT.

Notes: After receiving 12 weeks of presurgical axitinib treatment, one patient experienced a remarkable decrease in both the thrombus height and primitive tumor. The arrow indicates the distal end of the tumor thrombus. (A, B) The level of thrombus changed from level IV to III. (C) Widespread necrosis and extensive degeneration were observed in the photomicrograph of tumor thrombus. One patient showed no response to primitive tumor and tumor thrombus with 8 weeks of presurgical sorafenib treatment. The arrow indicates the distal end of the tumor thrombus. (D, E) The height of tumor thrombus remained stable at the level of second hepatic portal. (F) The photograph of tumor thrombus after TMT showed massive thrombosis with viable tumor cells.

Abbreviations: IVC, inferior vena cava; TMT, targeted molecular therapy.